Treg-enriched donor cell
Phase 1Biologic
Treg-enriched donor cell is one of 7 biologic programs targeting APL. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in APL
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 2
Tepadina
Jazz PharmaceuticalsPhase 1
Mekinist
NovartisPhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Alkeran
AApotex Inc.
Phase 1
Mesnex
BBaxter Healthcare Corporation
Phase 1
Treg-enriched donor cell
DDana-Farber Cancer Institute
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
APL1 trial
IS-free Treg HaploHCT
Recruiting·—·Phase 1·NCT04678401·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Treg-enriched donor cell. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- DDana-Farber Cancer Institute